Endocrine Abstracts

Background and Aims: The Omnipod® 5 AID System, which allows for personalized therapy through customisable glucose targets, is CE marked for use in individuals ages two years and older with type 1 diabetes and is commercially available in some European countries. This study aimed to evaluate real-world performance of the system in paediatric users in the United Kingdom (UK).

Methods: A retrospective analysis of continuous glucose monitoring (CGM) and insulin data from Omnipod 5 users with T1D aged 2 to <18 years in the UK whose guardian provided consent and had ≥90 days of data with sufficient CGM data (≥75% of days with ≥220 readings) available in the cloud-based data management system was conducted.

Results: Data from 14,386 users in the UK were available at the time of analysis. Preliminary results demonstrated a median time in target range (TIR; 3.9-10.0 mmol/l) of 66% (n = 7,808), 65% (n = 4,313), and 63% (n = 2,265) with use of the 6.1 mmol/l, 6.7 mmol/l, and 7.2-8.3 mmol/l targets, respectively. Time below range (TBR; <3.9 mmol/l) was low (median ≤ 1.90%) across glucose targets. Use of the lowest target (used by 54% of all users) was associated with the highest TIR with some age-related variability (2-5y: 67% [n = 263]; 6-12y: 67% [n = 3,310]; 13-17y: 64% [n = 4,235]), minimal TBR, and a high percentage of time spent in Automated Mode (median 95% across all age groups).

Conclusions: These real-world results in >14,300 Omnipod 5 paediatric users with T1D in the UK demonstrate the substantial glycaemic benefits of AID use. Additionally, these findings highlight the importance of target glucose selection and setting adjustments to optimise outcomes for children and adolescents using the Omnipod 5 System.